Xencor (XNCR) Tax Provisions (2016 - 2026)
Xencor (XNCR) posted quarterly Tax Provisions of $300000.0 for Q1 2026, down 25.0% year-over-year from $400000.0 in Q1 2025, and down 87.43% quarter-over-quarter from $2.4 million in Q4 2025.
Xencor (XNCR) Tax Provisions (2016 - 2026) Analysis & Trends
Xencor (XNCR) has reported Tax Provisions for 8 consecutive years, with $300000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Tax Provisions fell 25.0% year-over-year to $300000.0; the TTM figure through Mar 2026 stood at $2.4 million (up 20.82% YoY), while the FY2025 annual figure was $2.5 million, up 54.85% from the prior year.
- Tax Provisions declined to $300000.0 in Q1 2026 per XNCR's latest filing, from $2.4 million in the prior quarter.
- Across five years, Tax Provisions topped out at $13.7 million in Q4 2023 and bottomed at -$415000.0 in Q4 2022.
- Historically, Tax Provisions has averaged $2.3 million across 5 years, with a median of $744000.0 in 2022.
- Annual changes were most pronounced in 2023 — Tax Provisions soared 3392.05% — and 2024, when it plunged 88.16%.
- Xencor's Tax Provisions stood at -$415000.0 in 2022, then jumped by 3392.05% to $13.7 million in 2023, then slumped by 88.16% to $1.6 million in 2024, then surged by 47.62% to $2.4 million in 2025, then sank by 87.43% to $300000.0 in 2026.
- Business Quant data shows XNCR's Tax Provisions at $300000.0 in Q1 2026, $2.4 million in Q4 2025, and -$250000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - | -200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -200,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 2.39 Mn |
| Jun 30, 2025 | -250,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Dec 31, 2024 | 1.62 Mn |
| Dec 31, 2023 | 13.66 Mn |
| Dec 31, 2022 | -415,000.00 |
| Sep 30, 2022 | 1.09 Mn |
| Dec 31, 2019 | 5.11 Mn |
| Sep 30, 2019 | -350,000.00 |
| Jun 30, 2019 | 50,000.00 |
| Mar 31, 2019 | 900,000.00 |
| Dec 31, 2017 | -1.09 Mn |
| Sep 30, 2017 | 173,000.00 |
| Jun 30, 2017 | 280,000.00 |
| Mar 31, 2017 | 170,000.00 |
| Dec 31, 2016 | -159,000.00 |
| Sep 30, 2016 | -598,000.00 |
| Jun 30, 2016 | 1.75 Mn |